Noble Capital Markets Initiates Coverage on YS Biopharma With Outperform Rating and US$5.25 Price Target
- Written by PR Newswire
![]() |
GAITHERSBURG, Md., Nov. 14, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, is pleased to announce that Noble...















